NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has announced positive Phase 2a clinical trial results for its lead candidate NEO100 in recurrent brain cancer, a significant step forward for the company as it prepares to engage with the FDA on a registrational pathway. The data, covered by Stonegate Capital Partners in an updated research report, indicates that NEO100 met its primary endpoint, with a six-month progression-free survival (PFS) rate of 48.9% as measured by RANO 2.0 criteria, compared to a pre-specified benchmark of 20% (p=0.0047). The median overall survival (OS) reached 26.09 months, and the treatment demonstrated a favorable tolerability profile with no major toxicities reported.
These results are particularly notable given the current standard of care for recurrent brain cancer, which offers limited options. Management has cited that existing salvage therapies typically provide only 6–9 months of survival benefit, making the observed survival signal a compelling read-through. However, confirmation in a randomized controlled trial remains the next critical step. The company intends to request a Type B meeting with the FDA to discuss the design of a potential registrational trial, including endpoints and the approval pathway.
Beyond the NEO100 readout, NeOnc's second program, NEO212, has also gained regulatory momentum. The company has received Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway. This broadening of the pipeline adds to the investment case, as NEO100 is also being explored in meningioma and pediatric brain tumors, while NEO212 offers a differentiated second clinical program.
Financially, the company's second-quarter results reflect increased investment in research and development, with R&D expenses rising to $2.6 million from $0.7 million year-over-year. This spending is aligned with the advancement of clinical programs, though funding remains a key consideration as development activity expands.
The positive clinical data and regulatory clarity position NeOnc favorably for future growth. The company's ability to secure FDA alignment will be a near-term catalyst, potentially accelerating the path to approval for NEO100 and validating the broader platform. As the company moves forward, investors will be watching for updates on the Type B meeting and any additional data from ongoing trials.
